#ObesityMedicine #MetabolicHealth #GLP1 #ClinicalTrials #HealthcareInnovation #Semaglutide #Orforglipron #CagriSema #Retatrutide #Wegovy To view or add a comment, sign in : Eli Lilly and Company just released Phase 3 ATTAIN-MAINTAIN data on orforglipron, a once daily oral GLP-1 receptor agonist, and I think it speaks directly to one of the most painful realities my patients face: not losing weight, but it - Participants first completed 72 weeks on high-dose injectable semaglutide (Wegovy) or tirzepatide (Zepbound) in SURMOUNT-5, with very large average weight reductions
A full medical history, medication review, and clinical assessment are required
The Microbial Genomics Module of Qiagen CLC Workbench 12 was used for data analysis
Symptoms like nausea, bloating, and reflux are common when taking weight loss medications like Wegovy and Mounjaro
Magnesium can be helpful for various conditions, including feelings of worry, heart rhythm problems, ongoing tiredness, a condition called fibromyalgia, and high blood pressure
)
